Protara Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Protara Therapeutics, Inc. (TARA) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-44.60-40.42-65.95-47.25-33.98
Depreciation & Amortization0.330.340.250.120.20
Stock Based Compensation4.136.096.6910.369.75
Change in Working Capital4.01-4.140.54-0.520.63
Change in Accounts Payable1.380.850.630.040.20
Change in Other Working Capital1.01-4.991.371.050.43
Other Operating Activities1.011.011.371.059.75
Net Cash from Operating Activities-35.81-37.56-26.46-34.50-23.41
Investing Activities
Capital Expenditures-0.06-0.05-0.12-0.600.88
Acquisitions0.000.000.000.003.72
Purchases of Investments-29.3853.15-43.55-124.750.00
Sales/Maturities of Investments48.60-12.1958.6227.153.72
Other Investing Activities0.000.0058.6227.153.72
Net Cash from Investing Activities19.1653.1114.95-98.192.84
Financing Activities
Debt Repayment0.000.000.000.00-1.67
Common Stock Issued136.010.00-0.09-0.2375.44
Common Stock Repurchased-0.08-0.09-0.09-0.230.00
Other Financing Activities-0.08-0.090.000.0023.50
Net Cash from Financing Activities139.87-0.09-0.09-0.23189.40
Summary
Net Change in Cash123.2115.46-11.60-132.92168.83
Cash at Beginning of Period40.3324.8736.47169.390.56
Cash at End of Period163.54-49.7424.8736.47169.39
Free Cash Flow-35.87-37.60-26.58-35.10-24.29
Supplemental Disclosures
Interest Paid0.000.000.000.000.03